Androgen receptor signaling contributes to targeted therapy resistance in melanoma
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study published today in Nature. The findings provide a new target to combat therapeutic resistance and one possible answer to why men face a poorer prognosis than women when diagnosed with melanoma.
The AR is a type of nuclear...
Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma
ABSTRACTS: 2006, 2511
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of...
Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma
ABSTRACT: LBA11501
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses...